Last reviewed · How we verify
The Medicines Company — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
2 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo (D5W) | Placebo (D5W) | marketed | ||||
| Angiomax (bivalirudin) | Angiomax (bivalirudin) | phase 3 | Direct thrombin inhibitor | Thrombin (Factor IIa) | Cardiovascular | |
| Standard of Care IV antihypertensive | Standard of Care IV antihypertensive | phase 3 | ACE inhibitor | AT1 receptor | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Bayer · 1 shared drug class
- Beijing Tide Pharmaceutical Co., Ltd · 1 shared drug class
- Bioprojet · 1 shared drug class
- Boehringer Ingelheim · 1 shared drug class
- Ace Cells Lab Limited · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for The Medicines Company:
- The Medicines Company pipeline updates — RSS
- The Medicines Company pipeline updates — Atom
- The Medicines Company pipeline updates — JSON
Cite this brief
Drug Landscape (2026). The Medicines Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-medicines-company. Accessed 2026-05-16.